Company Overview of Hawaii Biotech, Inc.
Hawaii Biotech, Inc., a biotechnology company, researches and develops prophylactic vaccines for infectious diseases. The company provides a recombinant proteins production platform that has application to the manufacture vaccines, diagnostic kits, and research tools. Its technology platform develops vaccines for various diseases, including West Nile, dengue, tick borne encephalitis, influenza, hepatitis C, malaria, Japanese encephalitis, Ebola, Eastern equine encephalitis, and others. The company also develops recombinant subunit protein vaccines focusing on the quality of recombinant protein produced and its impact on immunogenicity; and GPI-0100, a saponin adjuvant useful in helping to el...
99-193 Aiea Heights Drive
Aiea, HI 96701
Founded in 1982
Key Executives for Hawaii Biotech, Inc.
Chief Executive Officer, President and Director
Chief Financial Officer and Chief Operations Officer
General Counsel, Vice President of Business Development, Secretary and Director
Director of Molecular Biology and Cell Culture
Compensation as of Fiscal Year 2015.
Hawaii Biotech, Inc. Key Developments
Soligenix Announces Collaboration with the University of Hawai'i at Manoa and Hawaii Biotech to Develop Heat Stable Ebola Vaccine
May 28 15
Soligenix, Inc. announced a collaboration agreement with Axel Lehrer, PhD of the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine (JABSOM), University of Hawai'i at Manoa (UH Manoa) and Hawaii Biotech, Inc. (HBI) to develop a heat stable subunit Ebola vaccine. Dr. Lehrer, a co-inventor of the Ebola vaccine with HBI, has shown proof of concept efficacy with subunit Ebola vaccines in non-human primates. Under the terms of the feasibility agreement, Soligenix will evaluate its proprietary vaccine thermostabilization technology, ThermoVax™, licensed from the University of Colorado, to stabilize components of the vaccine. Ultimately, the objective is to produce a thermostable Ebola vaccine for worldwide distribution that does not require cold storage. ThermoVax™ has been previously demonstrated to enhance thermostability of both ricin (RiVax™) and anthrax (VeloThrax™) subunit vaccines. The initial work on the potential Ebola vaccine will focus on a single protein subunit antigen. The most advanced Ebola vaccines involve the use of vesicular stomatitis virus (VSV) and adenovirus vectors – live, viral vectors which complicate the manufacturing, stability and storage requirements. Dr. Lehrer's vaccine is based on highly purified recombinant protein antigens, circumventing many of these manufacturing difficulties. Dr. Lehrer and HBI have developed a robust manufacturing process for the required proteins. Application of ThermoVax™ may allow for a product that can avoid the need for cold-chain distribution and storage, yielding a vaccine ideal for use in both the developed and developing world.
Hawaii Biotech Wins Department of Defense, Defense Threat Reduction Agency Contract
Mar 5 14
The Department of Defense, Defense Threat Reduction Agency, has awarded Hawaii Biotech, Inc., a contract to continue developing drugs to block botulinum toxin, the toxin that causes the life-threatening disease, botulism. There is no therapeutic drug currently available for the treatment of botulism. The award has a first-year period of performance through early 2014, followed by three option years with a total contract value of approximately $5.5 million. Under the contract, company will be working to improve its current anti-botulinum toxin inhibitor drug candidates that have demonstrated activity in pre-clinical testing. The goal will be to enhance the stability, bioavailability and safety of these drug candidates so they can be used in humans.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|